This is the third volume of our series Progress in Anti-Cancer Chemo-
therapy. Following the strategy of the first two volumes, it covers
selected aspects of progress in this fast moving field of Oncology, with
contribu- tions from some of the world's best known leaders in both
basic and clin- ical research. This year we focused on seven areas:
Three prominent Clinical investigators reviewed conceptual advances in
cancer research. Dr Buzdar presented a history and overview of the
protection of human subjects who participate in clinical research, and
the mechanisms developed to assure the ethical conduct of research on
human beings. Frei reviewed an exciting and rapidly moving area of che-
motherapy of solid tumors, including a cogent discussion of the issues
related to dose-intensification. Fisher summarized conceptual advances
in our therapeutic approach to breast cancer and the paradigm shifts
that lead us to our current management strategies. From this summary he
pro- jected breast cancer research into the future, a daunting task
under any circumstance. Fundamental research in cancer biology has been
responsible for our improved understanding of the development and
progession of malignant disease. Such understanding will lead to
improved diagnosis, therapy, and eventually, prevention. Isaacs reviews
the area of hereditary breast cancer, a topic undergoing rapid
transformation and with mUltiple impli- cations in the daily practice of
medicine. Fidler, an international expert in metastasis research reviews
the potential utility of angiogenesis inhib- itors in research and the
therapeutic ramifications.
